AZ Heads Talk Pipeline And Partnerships
The drugs major believes it has assembled a pipeline that is looking well stocked for several years to come.
You may also be interested in...
The cancer drug developer led by former Gilead R&D head Norbert Bischofberger will start a registrational trial for its recently acquired SYK inhibitor and the first trial for its CDK9 inhibitor.
AstraZeneca and Daiichi said their pivotal Phase II DESTINY-Breast01 trial assessing the HER2-targeting antibody drug conjugate trastuzumab deruxtecan met its primary endpoint, supporting global regulatory submission plans starting in this year’s second half.
Biologic's breakthrough designation is based on Phase IIb PATHWAY data that showed tezepelumab significantly reduced asthma exacerbations compared to placebo in severe asthma.